招募臨床研究志願者 (非小細胞肺癌) / Recruitment of Clinical Study Volunteers (Non-Small Cell Lung Cancer)
香港聯合腫瘤中心現正進行一項第三期、開放標籤、隨機臨床研究，針對已對免疫檢查點抑制劑聯合鉑類化療皆產生耐藥的晚期或轉移性非小細胞肺癌患者。所有新入組患者將接受 N-803 + 既往使用但已耐藥的免疫檢查點抑制劑 + 多西他賽（實驗組）或多西他賽單藥（對照組）。
Hong Kong United Oncology Centre is currently conducting a Phase 3 clinical study, open-label, randomized trial in patients with advanced/metastatic NSCLC who have acquired resistance to immune checkpoint inhibitor plus platinum-based chemotherapy. All newly enrolled patients will receive N-803 + prior failed checkpoint inhibitor + docetaxel (experimental arm) or docetaxel alone (control arm).
研究名稱 / Study Name
一項針對已對免疫檢查點抑制劑聯合鉑類化療皆產生耐藥的晚期或轉移性非小細胞肺癌患者，評估 N-803 聯合既往使用但已耐藥的免疫檢查點抑制劑與多西他賽治療方案，對照單獨使用多西他賽之第 3 期、開放標籤、隨機分配研究。 A Randomized, Open-label, Phase 3 Clinical Trial Of N-803 plus Prior failed checkpoint inhibitor And Docetaxel (experimental arm) Versus Docetaxel Monotherapy (control arm) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance To Immune Checkpoint Inhibitor Therapy.
ClinicalTrials.gov Identifier: NCT06745908
https://clinicaltrials.gov/study/NCT06745908
病人申請資格 / Patient Eligibility
- 確診的第四期（晚期或轉移性）非小細胞肺癌，並對免疫檢查點抑制劑（單獨使用或聯合化療）產生耐藥的患者。
- Patients with pathologically confirmed Stage IV (advanced or metastatic) Non-Small Cell Lung Cancer (NSCLC) who have acquired resistance to immune checkpoint inhibitor therapy.
研究報酬 / Study Compensation
- 相關治療藥物、研究影像掃描費用及醫生診症費用全免。
- Study medications, study required imaging, and doctor consultation will be free of charge.
研究過程 / Study Process
我們會作初步評估，以決定能否滿足進入該項臨床研究的條件。若您合乎資格參與本研究，您將被隨機分配接受以下其中一種治療方案： You will be screened for eligibility to participate in the trial. If you are eligible, you will be randomized to receive one of the following treatments:
- N-803 + 已耐藥的免疫檢查點抑制劑 + 多西他賽 (N-803 + Prior Failed Checkpoint Inhibitor + Docetaxel)
- 多西他賽單藥 (Docetaxel alone)
相關風險 / Related Risks
在研究期間，患者必需了解研究的目的及有機會帶來的潛在風險。您可能會因為接受上述試驗藥物治療而有不適，不適和風險可能會因人而異。 Participants should be aware of the objectives and potential risks of the trial. Discomfort and risks associated with the investigational treatments may vary from person to person.
聯絡方式 / Contact Information
有意參加者可經以下的方法與我們聯絡，以作進一步的了解： For further information, please contact us via the following methods:
- 有意參加者或欲了解初步評估詳情，可經以下方法與我們聯絡： Please contact us if you are interested or need further information:
- WhatsApp：5518 2992
- 電話：+852 2386 8002
- 電郵：Enquiry@hkuoc.hk
- 微信: hkuoc23868002
相關資源 / Related Resources
- 查詢更多研究項目：香港聯合腫瘤中心臨床研究頁面 / Find out more research projects: 臨床研究 ｜香港聯合腫瘤中心 ｜腫瘤科專科 – HKUOC
- HKUOC Clinical Research Page
- 了解更多關於非小細胞肺癌的資訊：醫院管理局香港癌症資料統計中心 / Learn more about NSCLC: Hong Kong Cancer Registry, Hospital Authority
研究贊助商 / Study Sponsor
ImmunityBio, Inc.
(註：宣傳內容已獲香港腫瘤學研究學會醫學倫理委員會審核並且批准刊登及發佈 / Remarks: This advertisement has been reviewed and approved for publication by the Research Ethics Committee of the Hong Kong Oncology Study Group.)